Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising

Novo Nordisk sued rival in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo‘s drugs.

Novo Nordisk sued rival in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo‘s drugs.

Subscribe to read this story ad-free

Get unlimited access to ad-free articles and exclusive content.

The Danish company filed the lawsuit in U.S. District Court in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo‘s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.